Inhibikase Therapeutics, Inc.
IKT· Nasdaq
IKTInhibikase Therapeutics, Inc.
Filed Mar 26, 2026 · 10-K · 85 days after period end · 0001193125-26-126371
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | $0.00 | $1.00 | $63.57K |
| Net Income | -$12.73M | -$12.13M | -$4.18M | -$4.28M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibikase Therapeutics, Inc. · CIK 1750149 · Engraved from SEC EDGAR
ended Dec 31, 2025 · filed Mar 26, 2026 · 85 d after period end
